Syneron Bio raised $150 million in a Series B to develop a peptide drug class, extending investment momentum from its prior $100 million round. The new capital supports program development and reflects continued investor interest in peptides positioned as potentially bridging characteristics of small molecules and antibodies. Stipple Bio also emerged with $100 million in Series A funding to identify more precise cancer targets, using its Pointillist platform focused on cancer-specific epitopes arising from post-translational modifications, protein conformation changes, or mis-localization. Both moves underscore how capital is flowing to mechanism- and platform-led oncology development efforts, especially where companies can articulate a differentiated product strategy beyond “target selection” alone.